Thank you for submitting your manuscript to The EMBO Journal. As the editor who would normally be handling this manuscript is away this week, I am therefore stepping in myself so we can avoid any delays. The decision here is quite straightforward, as all three referees really appreciated your manuscript. They have only minor changes to suggest as you can see in the comments to authors pasted below. I expect you will be able to deal with this quickly so things can move forward without delay.
When you send us your revision, please include a cover letter with an itemised list of all changes made in response to comments from review.
Thank you again for the opportunity to consider your work for publication. We look forward to receiving your revised manuscript.
REFEREE REPORTS:
Referee #1 (Remarks to the Author):
This is a very elegant study addressing the function of the TRF2 interacting protein hRAP1 at telomeres in human cells. The authors use a DNA binding domain from a yeast protein (Teb1) to target hRAP1 to telomeres, bypassing the need for TRF2. With this new tool, they show both in vitro and in vivo in Hela cells that hRAP1 inhibits the NHEJ pathway and prevents telomere fusions.
The experiments and the controls are well thought out. The demonstration is logical and easy to follow. It is a beautiful paper. Page 14 and page 16: the failure of hRAP1 to inhibit DNA damage signaling does not necessarily imply that hRAP1 protects TRF2-deficient telomeres downstream from the DNA damage response since NHEJ and ATM activation are to some extent independent pathways. For instance, hRAP1 might directly block Ligase IV and this would be unrelated to the DNA damage response.
A more explicit discussion about the fission yeast Taz1/Rap1 precedent would be fair. Figure 1C : the upper line should be extended leftward above lane 2.
Referee #2 (Remarks to the Author):
Sarthy et al This manuscript by Sarthy et al dissects the functions of TRF2 and hRAP1 in protecting telomeres from NHEJ-mediated end-to-end fusions. This is accomplished primarily through use of the hReb1 binding protein that in yeasts bind with high affinity to the human telomeric sequences. Targeting of Rap1 to the telomere by virtue of a protein fusion to hReb1 prevents fusions from taking place in vitro. It serves therefore as a means of targeting sequences to the telomere in a TRF2-independent fashion. To test this model in vivo, the authors tested a number of strains carrying the TRF2 B M dominant negative mutations that confer high rates of end-to-end fusion. The central finding is that the TRB-DNA binding domain fused to Rap1 is sufficient to bypass the need for TRF2 in protection against high rates of fusion. The TRB fusion alone is not sufficient and requires Rap1p. In an additional clever experiment, the authors create a deletion that abrogates binding of the site of homodimerization and of TRF2 association. This technique eliminates any effect of excess TRF2 binding. In contrast, based upon activation of the TRF2-specific effect of the ATM pathway and on the formation of TIFs, Rap1p is not sufficient to induce the DNA damage response. Rap1p function is therefore downstream of TRF2 as one of the repair functions needed to protect against fusion.
This manuscript describes convincingly the requirements for Rap1p protection against fusion. The clear picture that arises from this elegant study is DDR by TRF2 followed by a downstream function (defined by the function in the fusion protein) of hRAP1. Neither the nature of the function in NHEJ nor the source of damage signaling inhibition in strains lacking TRF2 is understood at this point. The data in the paper is of high quality and is statistically sound. The finding in this study is basic to an understanding of the role of the telomere in genetic instability (as mimicked by DBDM-induced fusions). Hence, this is a problem that will be of general interest to EMBO Journal.
However, there are a few items that require textual clarification that are enumerated below.
First, the homologue to Teb1 occurs in Saccharomyces cerevisiae as well as pombe.
Second, please refer to the "non-telomeric" ends as "scrambled" sequences for greater accuracy.
Third, the statement on pg. 1 of the supplement TRF2DBDM is expressed at similar levels independent of.." is written in a confusing style since it is unclear what is being compared.
Referee #3 (Remarks to the Author):
Within this manuscript the authors clearly establish the role RAP1 plays in NHEJ. Taking advantage of a fusion of RAP1 and the DNA binding domain of Teb the authors show that titrating RAP1 to telomeric DNA protects the DNA fragments form fusion in vitro. Then the authors demonstrate that the fusion protein localizes to telomeres in vivo. Expression of a dominant negative version of TRF2 caused efficient telomeric loss of RAP1, while TRF2 was lost only partially (while still leading to telomere uncapping), suggesting a role for RAP1 in TRF2 mediated end protection. Then the authors demonstrate that the TebDB neither plays a role in telomere protection, nor inhibits the effects of DNTRF2. However, RAP1, titrated to the telomeres via the TebDB, clearly protects telomeres from the deleterious effects of DNTRF2 expression. To exclude the possibility that DNTRF2 is titrated to telomeres and therefore inhibits uncapping and fusion formation, the authors titrate a RAP1 allele to telomeres that lacks the TRF2 interaction domain, which also protected telomeres. ATM still appeared activated in the cells expression the RAP1 fusions, and TIF were detectable, suggesting that RAP1 does not directly interfere with the DNA damage-signaling cascade.
This manuscript consist of a clear sequence of well planned and executed experiments that establish the role of RAP1 in chromosome protection. The reader walks away with new knowledge and a much better understanding of the telomeric complex and the proteins involved in protection of chromosome ends form NHEJ. Furthermore the experiments establish the fact that unprotected telomeres can exist without fusing to each other. This leads to the only small question I have about the manuscript: Will these cells eventually undergo irreversible arrest or apoptosis? One would expect the active damage response to lead to such consequences. The authors could test that or discuss their findings in this direction, as their system lends itself perfectly to demonstrate that unprotected telomeres do not need to undergo fusion-breakage cycles in order to cause severe cellular consequences. Also, I am sure the authors will eventually want to test their findings in a system where TRF2 has been genetically targeted, however, this referee suggests that these experiments are way beyond the scope of this manuscript. Reviewer 1:
We thank reviewer 1 for describing our work as an elegant study and a beautiful paper, as well as for her/his comments on the text. The reviewer raises an important point in that NHEJ and ATM activation are not necessarily linked. We have now included a discussion of this possibility on page 14. We feel that the statement "TRF2 directly inhibits damage signalling whereas hRAP1 blocks NHEJ downstream of the damage signal" on page 16 is justified as NHEJ activity necessitates some form of damage signal.
Following the reviewers suggestion we have expanded the discussion of S. pombe Taz1/Rap1 on page 17/18.
The line in panel 1C has been extended above lane 2.
Referee #2:
We thank reviewer 2 for describing our work as an elegant study and referring to the data as of high quality and statistically sound. We have addressed the requests for textual clarification as detailed below:
S. cerevisiae, like S. pombe and humans harbor numerous proteins containing myb/homeo/SANT domains. Psi-BLAST analysis of S. pombe Teb1 against the S. cerevisiae proteome identifies several Myb-domain containing proteins with the Bas1 transcription factor emerging as the top hit (E value 7e-24). The S. cerevisiae Reb1 protein mentioned by the reviewer displays only modest similarity with S. pombe Teb1 (E value = 0.005). As the S. cerevisiae proteins do not share the overall domain structure of Teb1 (Tandem myb domain near N-terminus) we are hesitant to refer to any of these proteins as Teb1 homologs. In addition, sequence comparison readily identifies S. pombe orthologs with higher scores than Teb1 for S. cerevisiae Bas1, Reb1 and Tbf1. To minimize confusion we have thus omitted discussion of Teb1-related proteins from S. cerevisiae.
The reference to non-telomeric ends has been changed to scrambled ends consistent with the labels in Figure 1 .
The legend for Supplementary figure 3 has been reworded to clarify which constructs are coexpressed in the experiment.
